More GSK ghostwriting examples surface

On the heels of ghostwriting allegations involving GlaxoSmithKline and a book purportedly authored by two doctors, Talking Points Memo points out additional publications--this time in medical journals--allegedly ghosted by the same writer on behalf of GSK. The company has said that its internal guidelines governing medical writers have since been tightened up. Report

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.